Market Cap
$313.3M
XOMAP
XOMA Royalty Corp
—
Market cap$313.3M
High Impact Filing (8/10) Biotech & Drug Discovery
Snapshot
The big-picture read on XOMAP right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
SEC Reports
6
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jul 15, 2026 listing_status
Jun 10, 2026 SEC Delisted: XOMAP — removed from the Nasdaq symbol directory
XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty filed its definitive proxy statement on Schedule 14A, setting a special stockholder meeting for July 13, 20
DEFM14A — Impact 8/10
XOMA Royalty filed its preliminary proxy statement/prospectus on Form S-4 with the SEC in connection with the proposed a
425 — Impact 7/10
XOMA Royalty Corp filed a DEFA14A (definitive additional proxy soliciting material) disclosing Amendment No. 1 to its Ag
DEFA14A — Impact 4/10
Analyst ratings buy % -25.6%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Aug 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Jul 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Jun 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| May 1, 2026 | 2 | 4 | 4 | 0 | 0 | 60% | |
| Apr 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Mar 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Feb 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% |
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 4 bullish, 0 bearish, 0 mixed, 2 neutral · avg impact 6.3/10.
BULLISHDEFM14A8/10
XOMA Royalty filed its definitive proxy statement on Schedule 14A, setting a special stockholder mee
Jun 10, 2026
BULLISH4257/10
XOMA Royalty filed its preliminary proxy statement/prospectus on Form S-4 with the SEC in connection
May 26, 2026
NEUTRALDEFA14A4/10
XOMA Royalty Corp filed a DEFA14A (definitive additional proxy soliciting material) disclosing Amend
May 18, 2026
BULLISHDEFA14A8/10
XOMA Royalty Corporation has agreed to be acquired by Ligand Pharmaceuticals for $39.00 per share in
Apr 27, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Jul 15, 2026
listing_status
Delisted: XOMAP — removed from the Nasdaq symbol directory
XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock
Jul 15, 2026
trading_halt
Halt Resumed: XOMAP — trading resumed after D (Security Deletion)
Halted 2026-07-13T23:50:00.000Z | Resumed 2026-07-15T04:00:01.000Z
Jul 13, 2026
trading_halt
Trading Halt: XOMAP — D (Security Deletion)
XOMA Ry 8.625 Ser A | Market: NASDAQ | Code: D — Security Deletion
Jul 13, 2026
trading_halt
Trading Halt: XOMAP — T12 (Additional Information Requested)
XOMA Ry 8.625 Ser A | Market: NASDAQ | Code: T12 — Additional Information Requested
Jun 12, 2026
dividend
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“ XOMA ” or the “<s
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Next FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Current Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Current FY | $0.00 | $0.00–$0.00 | — | — | — | $0.1B | — |
| Next Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for XOMAP.
Shares short
276
Settlement Jun 30, 2026
Change vs prior
-50.4%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈0.0%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Jul 13, 2026 | T12 | Info Requested | Not resumed |
| Jul 13, 2026 | D | Deletion | Resumed |
All XOMAP filing & press-release reports (6)
- DEFM14A reportJun 10, 2026
- 425 reportMay 26, 2026
- DEFA14A reportMay 18, 2026
- DEFA14A reportApr 27, 2026
- 8-K reportApr 27, 2026
- DEFA14A reportMar 30, 2026